Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Free Cash Flow: 2013-2024

Historic Free Cash Flow for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$398.1 million.

  • ImmunityBio's Free Cash Flow rose 30.74% to -$69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$324.8 million, marking a year-over-year increase of 25.18%. This contributed to the annual value of -$398.1 million for FY2024, which is 0.20% down from last year.
  • Latest data reveals that ImmunityBio reported Free Cash Flow of -$398.1 million as of FY2024, which was down 0.20% from -$397.3 million recorded in FY2023.
  • ImmunityBio's Free Cash Flow's 5-year high stood at -$173.4 million during FY2020, with a 5-year trough of -$415.7 million in FY2022.
  • Its 3-year average for Free Cash Flow is -$403.7 million, with a median of -$398.1 million in 2024.
  • Per our database at Business Quant, ImmunityBio's Free Cash Flow tumbled by 77.62% in 2021 and then rose by 4.41% in 2023.
  • Over the past 5 years, ImmunityBio's Free Cash Flow (Yearly) stood at -$173.4 million in 2020, then tumbled by 77.62% to -$308.0 million in 2021, then tumbled by 34.97% to -$415.7 million in 2022, then rose by 4.41% to -$397.3 million in 2023, then dropped by 0.20% to -$398.1 million in 2024.